Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15974161 | 1.00 | TYMP (0.62) | TYMPP2RY6TK2P2RY14TK1 | |
| SCHEMBL13714472 | 1.00 | TYMP (0.62) | TYMPP2RY6TK2P2RY14TK1 | |
| SCHEMBL3069438 | 1.00 | TYMP (0.62) | TYMPP2RY6TK2P2RY14TK1 | |
| SCHEMBL6246850 | 1.00 | TYMP (0.62) | TYMPP2RY6TK2P2RY14TK1 | |
| SCHEMBL13205014 | 1.00 | TYMP (0.62) | TYMPP2RY6TK2P2RY14TK1 | |
| SCHEMBL9710318 | 1.00 | TYMP (0.62) | TYMPP2RY6TK2P2RY14TK1 | |
| SCHEMBL5953147 | 0.94 | TYMP (0.57) | TYMPTK2TK1 | |
| SCHEMBL8535403 | 0.94 | TYMP (0.57) | TYMPTK2TK1 | |
| SCHEMBL8535399 | 0.94 | TYMP (0.57) | TYMPTK2TK1 | |
| SCHEMBL4626083 | 0.94 | TYMP (0.57) | TYMPTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-10738308-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT) | SIRNA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180265869-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE (3dT) | BANK OF AMERICA, N.A. | 2018-09-20 | — | — | US | disclosed |
| EP-3366772-A1 | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | Sirna Therapeutics, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9896688-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage | SIRNA THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2958998-B1 | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2958998-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | Sirna Therapeutics, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130607-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| EP-0975371-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999061462-A1 | ANTISENSE MODULATION OF CELLULAR ADHESION MOLECULE EXPRESSION AND TREATMENT OF CELLULAR ADHESION MOLECULE-ASSOCIATED DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999060010-A1 | COMPOSITIONS AND METHODS FOR THE PULMONARY DELIVERY OF NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999047707-A1 | ANTISENSE MODULATION OF LFA-3 | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999047708-A1 | ANTISENSE MODULATION OF PECAM-1 | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| CN-1214688-A | Sugar-modified gapped oligonucleotides | ISIS PHARMACEUTICALS INC (US) | 1999-04-21 | — | — | CN | disclosed |
| WO-1999009214-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS | ISIS PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999001579-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998046272-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998011123-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738308-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT) | SIN3A, NSUN3, AGO2 | TYMP 1409/4885P2RY6 3766/4885TK2 1316/4885 |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | NSUN2, AGO2, NSUN3 | TYMP 1326/4885P2RY6 3524/4885TK2 1163/4885 |
| US-20180265869-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE (3dT) | SIN3A, NSUN3, AGO2 | TYMP 1330/4885P2RY6 3796/4885TK2 1247/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | TYMP 23/4885P2RY6 433/4885TK2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.